Barzin Y. Nabet

Barzin Y. Nabet

Auto-generated profile, based on publicly available information

Barzin Y. Nabet

Genentech, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Cancer Cell
Verified
Journal Article
Closed access
CGCarl M. Gay
Carl M. Gay
CSC. Allison Stewart
C. Allison Stewart
EPElizabeth M. Park
Elizabeth M. Park
LDLixia Diao
Lixia Diao
SGSarah M. Groves
Sarah M. Groves
LBLauren Averett Byers
Lauren Averett Byers

1 October 2014 in Cell
Verified
Journal Article
Closed access
MBMirjam C. Boelens
Mirjam C. Boelens
TWTony J. Wu
Tony J. Wu
BNBarzin Y. Nabet
Barzin Y. Nabet
BXBihui Xu
Bihui Xu
YQYu Qiu
Yu Qiu
AMAndy J. Minn
Andy J. Minn

25 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JCJacob J. Chabon
Jacob J. Chabon
EHEmily G. Hamilton
Emily G. Hamilton
DKDavid M. Kurtz
David M. Kurtz
MEMohammad S. Esfahani
Mohammad S. Esfahani
EMEverett J. Moding
Everett J. Moding
MDMaximilian Diehn
Maximilian Diehn

28 September 2022 in Nature
Verified
Journal Article
Open access
PDF file
AKAkshay T. Krishnamurty
Akshay T. Krishnamurty
JSJustin A. Shyer
Justin A. Shyer
MTMinh Thai
Minh Thai
VGVineela Gandham
Vineela Gandham
MBMatthew B. Buechler
Matthew B. Buechler
STShannon J. Turley
Shannon J. Turley
Recent single-cell studies of cancer in both mice and humans have identified the emergence of a myofibroblast population specifically marked by the highly restricted leucine-rich-repeat-containing protein 15 (LRRC15)1–3. However, the molecular signals that underlie the development of LRRC15+ cancer-associated fibroblasts (CAFs) and their direct impact on anti-tumour immunity are uncharacterized. Here in mouse models of pancreatic cancer, we provide in vivo genetic evidence that TGFβ receptor type 2 signalling in healthy dermatopontin+ universal fibroblasts is essential for the development of cancer-associated LRRC15+ myofibroblasts. This axis also predominantly drives fibroblast lineage diversity in human cancers. Using newly developed Lrrc15–diphtheria toxin receptor knock-in mice to selectively deplete LRRC15+ CAFs, we show that depletion of this population markedly reduces the total tumour fibroblast content. Moreover, the CAF composition is recalibrated towards universal fibroblasts. This relieves direct suppression of tumour-infiltrating CD8+ T cells to enhance their effector function and augments tumour regression in response to anti-PDL1 immune checkpoint blockade. Collectively, these findings demonstrate that TGFβ-dependent LRRC15+ CAFs dictate the tumour-fibroblast setpoint to promote tumour growth. These cells also directly suppress CD8+ T cell function and limit responsiveness to checkpoint blockade. Development of treatments that restore the homeostatic fibroblast setpoint by reducing the population of pro-disease LRRC15+ myofibroblasts may improve patient survival and response to immunotherapy.

24 February 2022 in Cancer Cell
Verified
Journal Article
Closed access
NPNamrata S. Patil
Namrata S. Patil
BNBarzin Y. Nabet
Barzin Y. Nabet
SMSören Müller
Sören Müller
HKHartmut Koeppen
Hartmut Koeppen
WZWei Zou
Wei Zou
DSDavid S. Shames
David S. Shames

1 July 2017 in Cell
Verified
Journal Article
Closed access
BNBarzin Y. Nabet
Barzin Y. Nabet
YQYu Qiu
Yu Qiu
JSJacob E. Shabason
Jacob E. Shabason
TWTony J. Wu
Tony J. Wu
TYTaewon Yoon
Taewon Yoon
AMAndy J. Minn
Andy J. Minn